VIAF

Virtual International Authority File

Search

Postel-Vinay, Sophie Library of Congress/NACO Sudoc [ABES], France National Library of Israel ISNI National Library of France

Sophie Postel-Vinay Wikidata

VIAF ID: 246025754 (Personal)

Permalink: http://viaf.org/viaf/246025754

Open Section Close Section Preferred Forms

 

 

 

 

Open Section Close Section 4xx's: Alternate Name Forms (2)

Open Section Close SectionWorks

Title Sources
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Wikidata
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Wikidata
Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. Wikidata
A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials Wikidata
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Wikidata
Chromatin Regulators as a Guide for Cancer Treatment Choice Wikidata
Le ciblage de la voie du VEGF Library of Congress/NACO Sudoc [ABES], France National Library of Israel National Library of France
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Wikidata
Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Wikidata
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma Wikidata
[Dose finding methods for targeted agents: new perspectives]. Wikidata
ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform Wikidata
Etude de la déficience en ERCC1 dans le cancer bronchique non-à-petites cellules et recherche de léthalité synthétique. Sudoc [ABES], France
Exploiter les défauts de réparation de l’ADN pour moduler l’immunité anti-cancéreuse : une étude du potentiel immunologique des inhibiteurs de PARP. Sudoc [ABES], France
Exploiting DNA Repair Vulnerabilities to Modulate Anti-Cancer Immunity : a Study of the Immunological Potential of PARP inhibitors Sudoc [ABES], France
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. Wikidata
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Wikidata
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Wikidata
Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Wikidata
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Wikidata
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Wikidata
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Wikidata
Modifying phase I methodology to facilitate enrolment of molecularly selected patients. Wikidata
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Wikidata
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Wikidata
Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience. Wikidata
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Wikidata
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Wikidata
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Wikidata
Profilage moléculaire en oncologie pédiatrique – expérience de l'essai MOSCATO-01 // Caractérisation des sarcomes des tissus mous présentant des altérations de SMARCB1 traités par des inhibiteurs des HDAC. Sudoc [ABES], France
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Wikidata
Rationale for anti-OX40 cancer immunotherapy. Wikidata
Reovirus: Rationale and clinical trial update. Wikidata
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Wikidata
Synthetic lethality and functional study of DNA repair defects in ERCC1-deficient non-small-cell lung cancer Sudoc [ABES], France
Targeting FGFR Signaling in Cancer. Wikidata
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression? Wikidata

Open Section Close Section Selected Co-authors

Open Section Close Section Countries and Regions of Publication (1)

Open Section Close Section Publication Statistics

Open Section Close Section Selected Publishers (1)

Open Section Close Section About

Open Section Close Section History of VIAF ID:246025754 (6)